News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
CV Technologies Inc. Release: News Conference Notice: Results of Four City Study on COLD-FX Involving 780 Participants to Be Discussed by Principal Investigator, Dr. Gerald Predy and Company Officials
September 15, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
EDMONTON, ALBERTA--(Marketwire - Sept. 15, 2008) - CV Technologies Inc. (TSX:CVQ) - WHAT: News Conference to discuss results of COLD-FX's biggest trial to date.
Twitter
LinkedIn
Facebook
Email
Print
Events
MORE ON THIS TOPIC
Obesity
Analysts Home In on Safety as Novo, Lilly, Amgen Highlight Weight Loss Data at ADA
June 27, 2025
·
5 min read
·
Heather McKenzie
IN PARTNERSHIP WITH PATSNAP
Webinar: Beyond Theory: Real-World AI Wins in Life Science R&D, Faster & Smarter
June 25, 2025
·
1 min read
·
BioSpace Insights
Rare diseases
FDA Conditional Pathway Not Necessary, Rare Disease Experts Say, While Applauding Intent
June 24, 2025
·
3 min read
·
Heather McKenzie
Collaboration
Partner-Seeking Biotechs Find Plenty of Hands To Shake as BIO2025 Kicks Off
June 16, 2025
·
2 min read
·
Jef Akst
